Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.

About this Publication
Title
Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.
Pubmed ID
35534235 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Cancer Epidemiol Biomarkers Prev. 2022 May 9
Authors
In H, Sarkar S, Ward J, Friedmann P, Parides M, Yang J, Epplein M
Affiliations
  • Montefiore Medical Center/Albert Einstein College of Medicine, Department of Surgery, Bronx, New York.
  • Albert Einstein College of Medicine, Bronx, New York.
  • Division of Gastroenterology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
  • Department of Population Health Sciences, and Cancer Risk, Detection, and Interception Program, Duke Cancer Institute, Duke University, Durham, North Carolina.
Abstract

BACKGROUND: Gastric cancer (GC) lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a GC precursor, and may be useful to detect persons at increased risk of GC.

METHODS: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the US between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed GC and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I {less than or equal to} 70μg/L and pepsinogen I/II ratio {less than or equal to} 3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for GC are reported.

RESULTS: GC cases were more likely to be PG+ (31.4% vs 5.5%, p<0.001) at baseline than controls. Compared to PG-, PG+ was associated with an 8.5-fold increased risk for GC (95%CI=3.8-19.4). This risk remained significant after adjusting for Helicobacter pylori, family history of GC, education, smoking, and BMI (aOR 10.6; 95%CI=4.3-26.2). In subgroup analysis, PG+ individuals were 11-fold more like to develop non-cardia GC (OR 11.1; 95%CI=4.3-28.8); conversely, they were not significantly more likely to develop cardia GC (OR, 2.0; 95%CI=0.3-14.2). PG+ status yielded low sensitivity but high specificity for both non-cardia [44.3%; 93.6%] and cardia GC [5.7%; 97.2%].

CONCLUSIONS: Pre-diagnostic serum pepsinogen levels from a large, prospective cohort study were associated with risk of GC, particularly non-cardia GC.

IMPACT: PG status may identify individuals at higher risk of non-cardia GC for targeted screening or interventions.

Related CDAS Studies
Related CDAS Projects